Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma
نویسندگان
چکیده
منابع مشابه
Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma
Variant Burkitt-type translocation, t(8;22)(q24;q11), is very rare in plasma cell myeloma. We report a 51-year-old male patient with plasma cell myeloma, who showed t(8;22) (q24;q11). He suffered from pelvic pain for two months, and showed IgG, lambda type of monoclonal gammopathy (5.14 g/dL; 49.9% of protein). His bone marrow examination showed increased plasma cells (66.9% of all nucleated ce...
متن کاملPlasma cell myeloma
Myeloma is the most common neoplasm of bone.The majority is diagnosed with a bone marrow aspirate, rather than a bone biopsy. Most patients have disseminated disease, associated with a poor prognosis. Some have solitary myeloma with a more favourable clinical course but eventually, most become multifocal. A small percentage of patients have sclerotic bone lesions, which may be associated with p...
متن کاملOrbital plasma cell myeloma.
Orbital plasma cell myeloma is a rare condition. In a review of 222 intraorbital tumours, Forrest (1949) found only one case, and Offret (I951) reported two cases in a series of 676 orbital tumours. Clarke (I 953) emphasized the differentiation between the plasma cell myeloma of myelomatosis and the benign plasma cell tumour produced by chronic inflammation. The present report concerns a case p...
متن کاملcutaneous involvement in plasma cell myeloma: report of a case
abstract: plasma cellmyeloma constitutes about 10% of all hematologicmalignancies. metastatic cutaneous lesions without underlying bony involvement are rare and associated with advanced disease, poor prognosis and high tumor burden. igg is the most common subtype and igd is believed to have a more aggressive course.######
متن کاملTowards Stratified Medicine in Plasma Cell Myeloma
Plasma cell myeloma is a clinically heterogeneous malignancy accounting for approximately one to 2% of newly diagnosed cases of cancer worldwide. Treatment options, in addition to long-established cytotoxic drugs, include autologous stem cell transplant, immune modulators, proteasome inhibitors and monoclonal antibodies, plus further targeted therapies currently in clinical trials. Whilst treat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Hematology
سال: 2011
ISSN: 1738-7949
DOI: 10.5045/kjh.2011.46.2.135